Nohl André, Brune Bastian, Weichert Veronika, Standl Fabian, Stang Andreas, Dudda Marcel
Emergency Medical Services, Fire Brigade Oberhausen, 46047 Oberhausen, Germany.
Department of Emergency Medicine, BG Klinikum Duisburg, 47249 Duisburg, Germany.
Vaccines (Basel). 2022 Mar 9;10(3):411. doi: 10.3390/vaccines10030411.
(1) Background: The COVID-19 vaccination has caused uncertainty among employees and employers regarding vaccination reactions and incapacitation. At the time of our study, three vaccines are licensed in Germany to combat the COVID-19 pandemic (BioNTech/Pfizer (Comirnaty), AstraZeneca (Vaxzevria), and Moderna (Spikevax). We aim to assess how often and to what extent frontline healthcare workers had vaccination reactions after the first and second vaccination. The main focus is on the amount of sick leave after the vaccinations. (2) Methods: We create a web-based online questionnaire and deliver it to 270 medical directors in emergency medical services all over Germany. They are asked to make the questionnaire public to employees in their area of responsibility. To assess the association between independent variables and adverse effects of vaccination, we use log-binomial regression to estimate prevalence ratios (PR) with 95% confidence intervals (95%CI) for dichotomous outcomes (sick leave). (3) Results: A total of 3909 individuals participate in the survey for the first vaccination, of whom 3657 (94%) also provide data on the second vaccination. Compared to the first vaccination, mRNA-related vaccine reactions are more intense after the second vaccination, while vaccination reactions are less intense for vector vaccines. (4) Conclusion: Most vaccination reactions are physiological (local or systemic). Our results can help to anticipate the extent to which personnel will be unable to work after vaccination. Even among vaccinated HCWs, there seems to be some skepticism about future vaccinations. Therefore, continuous education and training should be provided to all professionals, especially regarding vaccination boosters. Our results contribute to a better understanding and can therefore support the control of the pandemic.
(1) 背景：新冠疫苗接种在员工和雇主中引发了关于疫苗反应和失能情况的不确定性。在我们开展研究时，德国有三种疫苗被批准用于抗击新冠疫情（辉瑞/BioNTech（复必泰）、阿斯利康（沃克威泽）和莫德纳（刺突疫苗））。我们旨在评估一线医护人员在首次和第二次接种疫苗后出现疫苗反应的频率和程度。主要关注接种疫苗后的病假天数。(2) 方法：我们创建了一个基于网络的在线问卷，并将其发送给德国各地紧急医疗服务部门的270名医疗主任。要求他们将问卷提供给其负责区域内的员工。为评估自变量与疫苗不良反应之间的关联，我们使用对数二项回归来估计二分结果（病假）的患病率比（PR）及其95%置信区间（95%CI）。(3) 结果：共有3909人参与了首次接种疫苗的调查，其中3657人（94%）也提供了第二次接种疫苗的数据。与首次接种相比，第二次接种后与信使核糖核酸相关的疫苗反应更强烈，而载体疫苗的反应则较弱。(4) 结论：大多数疫苗反应是生理性的（局部或全身性）。我们的结果有助于预测接种疫苗后人员无法工作的程度。即使在接种疫苗的医护人员中，对未来接种似乎也存在一些疑虑。因此，应向所有专业人员提供持续教育和培训，尤其是关于加强针接种方面。我们的结果有助于更好地理解，从而支持疫情防控。
